Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
NCT05091372
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
The goal of this study is to find a way to help more patients with a type of cancer called multiple myeloma. They want to increase the number of patients who have a negative test result after treatment. The treatment involves using a medicine called belantamab mafodotin along with another medicine called lenalidomide. They will study how well this treatment works for patients who have just been diagnosed with multiple myeloma and have had a transplant.
The goal of this study is to find a way to help more patients with a type of cancer called multiple myeloma. They want to increase the number of patients who have a negative test result after treatment. The treatment involves using a medicine called belantamab mafodotin along with another medicine called lenalidomide. They will study how well this treatment works for patients who have just been diagnosed with multiple myeloma and have had a transplant.
Third Opinion AI Generated Synopsis
Trial Summary
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
